Switch to ATV ± r-containing regimen
SWAN
Original article : Clin Infect Dis. 2007 Jun 1;44(11):1484-92 – J Gatell
Last update :
28/03/2014
Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK
- Switching to a simplified PI-based regimen containing ATV provided better maintenance of virologic suppression with lower rates of virologic rebound and treatment failure than those observed with continued, unmodified therapy
- Safety and tolerability were similar in both groups
- But lipid parameters improved in the ATV group
- Hyperbilirubinemia was frequent on ATV
Design :
Objective :
- Non inferiority in the proportion of patients with virologic rebound at W48 (upper limit of the 95% CI for the difference = 12%, 90% power)
- Virologic rebound: 2 consecutive HIV-1 RNA ≥ 50 c/mL on study, or last on-study HIV-1 RNA ≥ 50 c/mL followed by study discontinuation
Baseline characteristics and patient disposition :
- PI use at screening was LPV/r: 37%, NFV: 33%, IDV/r: 10%, IDV: 8%, SQV/r: 6%, SQV: 3%
- TDF was part of the ARV regimen in 37 patients (9%) [26 in the ATV group]
Virologic rebound (HIV-1 RNA ≥ 50 c/mL)
Treatment failure
Fasting plasma lipids changes from baseline to week 48 :
Mean changes from baseline in lipid parameters at W48 :
HDL-C,high density lipoprotein cholesterol ; LDL-C, low-density lipoprotein cholesterol ; PI, protease inhibitor ; TC, total cholesterol
Adverse events by W48 :
AST and ALT elevations were more frequent in patients with hepatitis co-infection
Download the slides
